Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 101 entries
Sorted by: Best Match Show Resources per page
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.

Cancer cell

Wilson WH, Wright GW, Huang DW, Hodkinson B, Balasubramanian S, Fan Y, Vermeulen J, Shreeve M, Staudt LM.
PMID: 34739844
Cancer Cell. 2021 Nov 03; doi: 10.1016/j.ccell.2021.10.006. Epub 2021 Nov 03.

In diffuse large B cell lymphoma (DLBCL), tumors belonging to the ABC but not GCB gene expression subgroup rely upon chronic active B cell receptor signaling for viability, a dependency that is targetable by ibrutinib. A phase III trial...

Cite
Wilson WH, Wright GW, Huang DW, et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021;doi: 10.1016/j.ccell.2021.10.006.
Wilson, W. H., Wright, G. W., Huang, D. W., Hodkinson, B., Balasubramanian, S., Fan, Y., Vermeulen, J., Shreeve, M., & Staudt, L. M. (2021). Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer cell, . https://doi.org/10.1016/j.ccell.2021.10.006
Wilson, Wyndham H, et al. "Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL." Cancer cell vol. (2021). doi: https://doi.org/10.1016/j.ccell.2021.10.006
Wilson WH, Wright GW, Huang DW, Hodkinson B, Balasubramanian S, Fan Y, Vermeulen J, Shreeve M, Staudt LM. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021 Nov 03; doi: 10.1016/j.ccell.2021.10.006. Epub 2021 Nov 03. PMID: 34739844.
Copy Download .nbib Format: NLM
COVID-19 vaccines and women's security.

Lancet (London, England)

Harman S, Herten-Crabb A, Morgan R, Smith J, Wenham C.
PMID: 33357493
Lancet. 2021 Jan 30;397(10272):357-358. doi: 10.1016/S0140-6736(20)32727-6. Epub 2020 Dec 23.

No abstract available.

Cite
Harman S, Herten-Crabb A, Morgan R, et al. COVID-19 vaccines and women's security. Lancet. 2020;397(10272):357-358doi: 10.1016/S0140-6736(20)32727-6.
Harman, S., Herten-Crabb, A., Morgan, R., Smith, J., & Wenham, C. (2021). COVID-19 vaccines and women's security. Lancet (London, England), 397(10272), 357-358. https://doi.org/10.1016/S0140-6736(20)32727-6
Harman, Sophie, et al. "COVID-19 vaccines and women's security." Lancet (London, England) vol. 397,10272 (2021): 357-358. doi: https://doi.org/10.1016/S0140-6736(20)32727-6
Harman S, Herten-Crabb A, Morgan R, Smith J, Wenham C. COVID-19 vaccines and women's security. Lancet. 2021 Jan 30;397(10272):357-358. doi: 10.1016/S0140-6736(20)32727-6. Epub 2020 Dec 23. PMID: 33357493; PMCID: PMC7757348.
Copy Download .nbib Format: NLM
Severe ectopic Cushing's syndrome.

Proceedings (Baylor University. Medical Center)

Modi A, Olejarski J, Windham A.
PMID: 33100538
Proc (Bayl Univ Med Cent). 2020 Jun 22;33(4):601-602. doi: 10.1080/08998280.2020.1772183.

We present a rare case of severe ectopic Cushing's syndrome in a 39-year-old woman with a rapid onset of signs and symptoms and severe hypokalemia. Further workup demonstrated an adrenocorticotropic hormone-secreting metastatic high-grade neuroendocrine carcinoma.

Cite
Modi A, Olejarski J, Windham A. Severe ectopic Cushing's syndrome. Proc (Bayl Univ Med Cent). 2020;33(4):601-602doi: 10.1080/08998280.2020.1772183.
Modi, A., Olejarski, J., & Windham, A. (2020). Severe ectopic Cushing's syndrome. Proceedings (Baylor University. Medical Center), 33(4), 601-602. https://doi.org/10.1080/08998280.2020.1772183
Modi, Ankur, et al. "Severe ectopic Cushing's syndrome." Proceedings (Baylor University. Medical Center) vol. 33,4 (2020): 601-602. doi: https://doi.org/10.1080/08998280.2020.1772183
Modi A, Olejarski J, Windham A. Severe ectopic Cushing's syndrome. Proc (Bayl Univ Med Cent). 2020 Jun 22;33(4):601-602. doi: 10.1080/08998280.2020.1772183. PMID: 33100538; PMCID: PMC7549967.
Copy Download .nbib Format: NLM
COVID-19 and the Gendered Use of Emojis on Twitter: Infodemiology Study.

Journal of medical Internet research

Al-Rawi A, Siddiqi M, Morgan R, Vandan N, Smith J, Wenham C.
PMID: 33052871
J Med Internet Res. 2020 Nov 05;22(11):e21646. doi: 10.2196/21646.

BACKGROUND: The online discussion around the COVID-19 pandemic is multifaceted, and it is important to examine the different ways by which online users express themselves. Since emojis are used as effective vehicles to convey ideas and sentiments, they can...

Cite
Al-Rawi A, Siddiqi M, Morgan R, et al. COVID-19 and the Gendered Use of Emojis on Twitter: Infodemiology Study. J Med Internet Res. 2020;22(11):e21646doi: 10.2196/21646.
Al-Rawi, A., Siddiqi, M., Morgan, R., Vandan, N., Smith, J., & Wenham, C. (2020). COVID-19 and the Gendered Use of Emojis on Twitter: Infodemiology Study. Journal of medical Internet research, 22(11), e21646. https://doi.org/10.2196/21646
Al-Rawi, Ahmed, et al. "COVID-19 and the Gendered Use of Emojis on Twitter: Infodemiology Study." Journal of medical Internet research vol. 22,11 (2020): e21646. doi: https://doi.org/10.2196/21646
Al-Rawi A, Siddiqi M, Morgan R, Vandan N, Smith J, Wenham C. COVID-19 and the Gendered Use of Emojis on Twitter: Infodemiology Study. J Med Internet Res. 2020 Nov 05;22(11):e21646. doi: 10.2196/21646. PMID: 33052871; PMCID: PMC7647473.
Copy Download .nbib Format: NLM
Augustus Lockman Warner: Founder Medical College of Virginia, First Professor of Surgery and First Dean.

Annals of medical history

Blanton WB.
PMID: 33943712
Ann Med Hist. 1942 Jan;4(1):1-9.

No abstract available.

Cite
Blanton WB. Augustus Lockman Warner: Founder Medical College of Virginia, First Professor of Surgery and First Dean. Ann Med Hist. 1942;4(1):1-9
Blanton, W. B. (1942). Augustus Lockman Warner: Founder Medical College of Virginia, First Professor of Surgery and First Dean. Annals of medical history, 4(1), 1-9.
Blanton, Wyndham B. "Augustus Lockman Warner: Founder Medical College of Virginia, First Professor of Surgery and First Dean." Annals of medical history vol. 4,1 (1942): 1-9.
Blanton WB. Augustus Lockman Warner: Founder Medical College of Virginia, First Professor of Surgery and First Dean. Ann Med Hist. 1942 Jan;4(1):1-9. PMID: 33943712; PMCID: PMC7942453.
Copy Download .nbib Format: NLM
Madstones: With an Account of Several from Virginia.

Annals of medical history

Blanton WB.
PMID: 33943656
Ann Med Hist. 1935 May;7(3):268-273.

No abstract available.

Cite
Blanton WB. Madstones: With an Account of Several from Virginia. Ann Med Hist. 1935;7(3):268-273
Blanton, W. B. (1935). Madstones: With an Account of Several from Virginia. Annals of medical history, 7(3), 268-273.
Blanton, Wyndham B. "Madstones: With an Account of Several from Virginia." Annals of medical history vol. 7,3 (1935): 268-273.
Blanton WB. Madstones: With an Account of Several from Virginia. Ann Med Hist. 1935 May;7(3):268-273. PMID: 33943656; PMCID: PMC7942352.
Copy Download .nbib Format: NLM
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA.

Nature biotechnology

Kurtz DM, Soo J, Co Ting Keh L, Alig S, Chabon JJ, Sworder BJ, Schultz A, Jin MC, Scherer F, Garofalo A, Macaulay CW, Hamilton EG, Chen B, Olsen M, Schroers-Martin JG, Craig AFM, Moding EJ, Esfahani MS, Liu CL, Dührsen U, Hüttmann A, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA.
PMID: 34294911
Nat Biotechnol. 2021 Jul 22; doi: 10.1038/s41587-021-00981-w. Epub 2021 Jul 22.

Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the limited sensitivity of current detection methods reduces its utility for diagnosing minimal residual disease. Here we describe phased variant enrichment and detection sequencing (PhasED-seq), a method...

Cite
Kurtz DM, Soo J, Co Ting Keh L, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol. 2021;doi: 10.1038/s41587-021-00981-w.
Kurtz, D. M., Soo, J., Co Ting Keh, L., Alig, S., Chabon, J. J., Sworder, B. J., Schultz, A., Jin, M. C., Scherer, F., Garofalo, A., Macaulay, C. W., Hamilton, E. G., Chen, B., Olsen, M., Schroers-Martin, J. G., Craig, A. F. M., Moding, E. J., Esfahani, M. S., Liu, C. L., Dührsen, U., Hüttmann, A., Casasnovas, R. O., Westin, J. R., Roschewski, M., Wilson, W. H., Gaidano, G., Rossi, D., Diehn, M., & Alizadeh, A. A. (2021). Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nature biotechnology, . https://doi.org/10.1038/s41587-021-00981-w
Kurtz, David M, et al. "Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA." Nature biotechnology vol. (2021). doi: https://doi.org/10.1038/s41587-021-00981-w
Kurtz DM, Soo J, Co Ting Keh L, Alig S, Chabon JJ, Sworder BJ, Schultz A, Jin MC, Scherer F, Garofalo A, Macaulay CW, Hamilton EG, Chen B, Olsen M, Schroers-Martin JG, Craig AFM, Moding EJ, Esfahani MS, Liu CL, Dührsen U, Hüttmann A, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol. 2021 Jul 22; doi: 10.1038/s41587-021-00981-w. Epub 2021 Jul 22. PMID: 34294911.
Copy Download .nbib Format: NLM
Update on the Pathogenesis, Diagnosis, and Therapy of AIDS-related Lymphoma.

Current infectious disease reports

Little RF, Wilson WH.
PMID: 12642005
Curr Infect Dis Rep. 2003 Apr;5(2):176-184. doi: 10.1007/s11908-003-0055-1.

AIDS-related non-Hodgkin's lymphoma (ARL) is an opportunistic malignancy that foreshortens life more than any other commonly occurring HIV-associated cancer. Treatment strategies include low-dose chemotherapy, chemotherapy given with antiretroviral therapy, and infusional chemotherapy regimens. Rituximab, an anti-CD20 monoclonal antibody, has...

Cite
Little RF, Wilson WH. Update on the Pathogenesis, Diagnosis, and Therapy of AIDS-related Lymphoma. Curr Infect Dis Rep. 2003;5(2):176-184doi: 10.1007/s11908-003-0055-1.
Little, R. F., & Wilson, W. H. (2003). Update on the Pathogenesis, Diagnosis, and Therapy of AIDS-related Lymphoma. Current infectious disease reports, 5(2), 176-184. https://doi.org/10.1007/s11908-003-0055-1
Little, Richard F., and Wilson, Wyndham H.. "Update on the Pathogenesis, Diagnosis, and Therapy of AIDS-related Lymphoma." Current infectious disease reports vol. 5,2 (2003): 176-184. doi: https://doi.org/10.1007/s11908-003-0055-1
Little RF, Wilson WH. Update on the Pathogenesis, Diagnosis, and Therapy of AIDS-related Lymphoma. Curr Infect Dis Rep. 2003 Apr;5(2):176-184. doi: 10.1007/s11908-003-0055-1. PMID: 12642005.
Copy Download .nbib Format: NLM
Characterization and evaluation of C18 HPLC stationary phases based on ethyl-bridged hybrid organic/inorganic particles.

Analytical chemistry

Wyndham KD, O'Gara JE, Walter TH, Glose KH, Lawrence NL, Alden BA, Izzo GS, Hudalla CJ, Iraneta PC.
PMID: 14670036
Anal Chem. 2003 Dec 15;75(24):6781-8. doi: 10.1021/ac034767w.

The characterization and evaluation of three novel 5-microm HPLC column packings, prepared using ethyl-bridged hybrid organic/inorganic materials, is described. These highly spherical hybrid particles, which vary in specific surface area (140, 187, and 270 m(2)/g) and average pore diameter...

Cite
Wyndham KD, O'Gara JE, Walter TH, et al. Characterization and evaluation of C18 HPLC stationary phases based on ethyl-bridged hybrid organic/inorganic particles. Anal Chem. 2003;75(24):6781-8doi: 10.1021/ac034767w.
Wyndham, K. D., O'Gara, J. E., Walter, T. H., Glose, K. H., Lawrence, N. L., Alden, B. A., Izzo, G. S., Hudalla, C. J., & Iraneta, P. C. (2003). Characterization and evaluation of C18 HPLC stationary phases based on ethyl-bridged hybrid organic/inorganic particles. Analytical chemistry, 75(24), 6781-8. https://doi.org/10.1021/ac034767w
Wyndham, Kevin D, et al. "Characterization and evaluation of C18 HPLC stationary phases based on ethyl-bridged hybrid organic/inorganic particles." Analytical chemistry vol. 75,24 (2003): 6781-8. doi: https://doi.org/10.1021/ac034767w
Wyndham KD, O'Gara JE, Walter TH, Glose KH, Lawrence NL, Alden BA, Izzo GS, Hudalla CJ, Iraneta PC. Characterization and evaluation of C18 HPLC stationary phases based on ethyl-bridged hybrid organic/inorganic particles. Anal Chem. 2003 Dec 15;75(24):6781-8. doi: 10.1021/ac034767w. PMID: 14670036.
Copy Download .nbib Format: NLM
Draft Genome Sequence of a Multidrug-Resistant Klebsiella quasipneumoniae subsp. similipneumoniae Isolate from a Clinical Source.

Genome announcements

Ozer EA, Morris AR, Krapp F, Henry CS, Tyo KE, Lathem WW, Hauser AR.
PMID: 27231362
Genome Announc. 2016 May 26;4(3). doi: 10.1128/genomeA.00422-16.

We report here the draft genome sequence of a multidrug-resistant clinical isolate of Klebsiella quasipneumoniae subsp. similipneumoniae, KP_Z4175. This strain, isolated as part of a hospital infection-control screening program, is resistant to multiple β-lactam antibiotics, aminoglycosides, and trimethoprim-sulfamethoxazole.

Cite
Ozer EA, Morris AR, Krapp F, et al. Draft Genome Sequence of a Multidrug-Resistant Klebsiella quasipneumoniae subsp. similipneumoniae Isolate from a Clinical Source. Genome Announc. 2016;4(3)doi: 10.1128/genomeA.00422-16.
Ozer, E. A., Morris, A. R., Krapp, F., Henry, C. S., Tyo, K. E., Lathem, W. W., & Hauser, A. R. (2016). Draft Genome Sequence of a Multidrug-Resistant Klebsiella quasipneumoniae subsp. similipneumoniae Isolate from a Clinical Source. Genome announcements, 4(3), . https://doi.org/10.1128/genomeA.00422-16
Ozer, Egon A, et al. "Draft Genome Sequence of a Multidrug-Resistant Klebsiella quasipneumoniae subsp. similipneumoniae Isolate from a Clinical Source." Genome announcements vol. 4,3 (2016). doi: https://doi.org/10.1128/genomeA.00422-16
Ozer EA, Morris AR, Krapp F, Henry CS, Tyo KE, Lathem WW, Hauser AR. Draft Genome Sequence of a Multidrug-Resistant Klebsiella quasipneumoniae subsp. similipneumoniae Isolate from a Clinical Source. Genome Announc. 2016 May 26;4(3). doi: 10.1128/genomeA.00422-16. PMID: 27231362; PMCID: PMC4882943.
Copy Download .nbib Format: NLM
Define the human right to science.

Science (New York, N.Y.)

Wyndham JM, Vitullo MW.
PMID: 30498101
Science. 2018 Nov 30;362(6418):975. doi: 10.1126/science.aaw1467.

No abstract available.

Cite
Wyndham JM, Vitullo MW. Define the human right to science. Science. 2018;362(6418):975doi: 10.1126/science.aaw1467.
Wyndham, J. M., & Vitullo, M. W. (2018). Define the human right to science. Science (New York, N.Y.), 362(6418), 975. https://doi.org/10.1126/science.aaw1467
Wyndham, Jessica M, and Vitullo, Margaret Weigers. "Define the human right to science." Science (New York, N.Y.) vol. 362,6418 (2018): 975. doi: https://doi.org/10.1126/science.aaw1467
Wyndham JM, Vitullo MW. Define the human right to science. Science. 2018 Nov 30;362(6418):975. doi: 10.1126/science.aaw1467. PMID: 30498101.
Copy Download .nbib Format: NLM
Preventing SARS-CoV-2 infection by blocking a tissue serine protease.

Therapeutic advances in infectious disease

Jankousky KC, Schultz J, Windham S, Henao-Martínez AF, Franco-Paredes C, Shapiro L.
PMID: 32577236
Ther Adv Infect Dis. 2020 Jun 10;7:2049936120933076. doi: 10.1177/2049936120933076. eCollection 2020.

Currently, there are no proven pharmacologic interventions to reduce the clinical impact and prevent complications of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, the cause of the ongoing Coronavirus Disease of 2019 (COVID-19) pandemic. Selecting specific pharmacological...

Cite
Jankousky KC, Schultz J, Windham S, et al. Preventing SARS-CoV-2 infection by blocking a tissue serine protease. Ther Adv Infect Dis. 2020;7:2049936120933076doi: 10.1177/2049936120933076.
Jankousky, K. C., Schultz, J., Windham, S., Henao-Martínez, A. F., Franco-Paredes, C., & Shapiro, L. (2020). Preventing SARS-CoV-2 infection by blocking a tissue serine protease. Therapeutic advances in infectious disease, 72049936120933076. https://doi.org/10.1177/2049936120933076
Jankousky, Katherine C, et al. "Preventing SARS-CoV-2 infection by blocking a tissue serine protease." Therapeutic advances in infectious disease vol. 7 (2020): 2049936120933076. doi: https://doi.org/10.1177/2049936120933076
Jankousky KC, Schultz J, Windham S, Henao-Martínez AF, Franco-Paredes C, Shapiro L. Preventing SARS-CoV-2 infection by blocking a tissue serine protease. Ther Adv Infect Dis. 2020 Jun 10;7:2049936120933076. doi: 10.1177/2049936120933076. eCollection 2020. PMID: 32577236; PMCID: PMC7288835.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 101 entries